{"paper_id": "3e3d92367e7223cd85446f55e953520b270e3c94", "metadata": {"title": "Drafting of the manuscript: Alanio", "authors": [{"first": "Alexandre", "middle": [], "last": "Alanio", "suffix": "", "affiliation": {}, "email": ":alexandre.alanio@aphp.fr."}, {"first": "Sebastian", "middle": [], "last": "Voicu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Bruno", "middle": [], "last": "M\u00e9garbane", "suffix": "", "affiliation": {}, "email": ""}, {"first": "St\u00e9phane", "middle": [], "last": "Bretagne", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": "Word count: 1000 words + 10 references + 1 table + 1 Figure   45 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [{"start": 53, "end": 64, "text": "Figure   45", "ref_id": null}], "section": "44"}, {"text": "The copyright holder for this preprint this version posted May 22, 2020. ", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "72"}, {"text": "The copyright holder for this preprint this version posted May 22, 2020. ", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "Three out of five P. jirovecii RTqPCR-positive patients received co-trimoxazole as prophylaxis. To date, 93 one patient has died, one patient is still mechanically ventilated and the three others including the two 94 patients who were not treated with co-trimoxazole have been discharged from the hospital.", "cite_spans": [], "ref_spans": [], "section": "92"}, {"text": "We found an unexpectedly high proportion of critically ill COVID-19 patients detected with P. jirovecii 98 (17%) as compared to previous findings in influenza patients (~7%) (4).", "cite_spans": [], "ref_spans": [], "section": "97"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "99"}, {"text": "The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105296 doi: medRxiv preprint", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The presence of P. jirovecii in the healthy adult population has been measured using oropharyngeal 100 wash samples obtained by gargling and examined by conventional or nested PCR methods. 5 However, 101 experts agree that the reported prevalence (~20%) has been overestimated due to technical issues such as ", "cite_spans": [], "ref_spans": [], "section": "5"}, {"text": "Our study limitations include the relatively small number of patients, the single-center setting, and the 123 short study period. However, to the best of our knowledge, this is the first study evaluating the prevalence 124 of P. jirovecii in COVID-19 patients. Because we focused on critically ill COVID-19 patients, prevalence 125 of P. jirovecii in less severe patients remains to be determined.", "cite_spans": [], "ref_spans": [], "section": "122"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "126"}, {"text": "The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105296 doi: medRxiv preprint 6", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "In conclusion, based on our findings, we advocate systematically searching for P. jirovecii in deep 127 respiratory specimens in critically ill COVID-19 patients. We believe that this strategy may be useful in 128 limiting enhanced inflammation due to the presence of P. jirovecii in the lung and avoiding inter-patient P. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": "The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105296 doi: medRxiv preprint", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Clinical features of patients infected with 2019 novel 140 coronavirus in Wuhan, China", "authors": [{"first": "C", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "L", "middle": [], "last": "Ren", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "497--506", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "ECIL guidelines for the 145 diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell 146 transplant recipients", "authors": [{"first": "A", "middle": [], "last": "3-Alanio", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Hauser", "suffix": ""}, {"first": "K", "middle": [], "last": "Lagrou", "suffix": ""}, {"first": "W", "middle": ["J"], "last": "Melchers", "suffix": ""}, {"first": "J", "middle": [], "last": "Helweg-Larsen", "suffix": ""}, {"first": "O", "middle": [], "last": "Matos", "suffix": ""}], "year": 2016, "venue": "J Antimicrob Chemother", "volume": "71", "issn": "", "pages": "2386--2396", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Influenza 148 virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality", "authors": [{"first": "M", "middle": ["C"], "last": "Beumer", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Koch", "suffix": ""}, {"first": "D", "middle": [], "last": "Van Beuningen", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Oudelashof", "suffix": ""}, {"first": "F", "middle": ["L"], "last": "Van De Veerdonk", "suffix": ""}, {"first": "E", "middle": [], "last": "Kolwijck", "suffix": ""}], "year": 2019, "venue": "J Crit Care", "volume": "149", "issn": "", "pages": "59--65", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Pneumocystis 151 jirovecii in general population", "authors": [{"first": "F", "middle": ["J"], "last": "Medrano", "suffix": ""}, {"first": "M", "middle": [], "last": "Montes-Cano", "suffix": ""}, {"first": "M", "middle": [], "last": "Conde", "suffix": ""}, {"first": "C", "middle": [], "last": "De La Horra", "suffix": ""}, {"first": "N", "middle": [], "last": "Respaldiza", "suffix": ""}, {"first": "A", "middle": [], "last": "Gasch", "suffix": ""}], "year": 2005, "venue": "Emerg Infect Dis", "volume": "11", "issn": "", "pages": "245--250", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Longitudinal characteristics of lymphocyte responses and 153 cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients", "authors": [{"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "S", "middle": [], "last": "Li", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "B", "middle": [], "last": "Liang", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "EBioMedicine", "volume": "55", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "\u03b2-D-glucan testing is important for diagnosis of invasive fungal infections", "authors": [{"first": "E", "middle": ["S"], "last": "Theel", "suffix": ""}, {"first": "C", "middle": ["D"], "last": "Doern", "suffix": ""}], "year": 2013, "venue": "J Clin 155 Microbiol", "volume": "51", "issn": "", "pages": "3478--3483", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "consecutive patients admitted to the ICU between March 15 th and April 15 th 2020 were enrolled. This 62 study was part of the French COVID-19 cohort registry conducted by the REACTing consortium (REsearch 63 and ACTion targeting emerging infectious diseases) and directed by INSERM (Institut national de la sant\u00e9 64 et de la recherche m\u00e9dicale) and ISARIC (International Severe Acute Respiratory and Emerging Infection 65 Consortium). Our institutional ethics committee approved the study (IDRCB, 2020-A00256-33; CPP, 11-66 20 20.02.04.68737). When possible, signed informed consent was obtained from the patients or the next of 67 kin.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Upon reception in the laboratory, all specimens including bronchoalveolar lavage (BAL) fluids and dTT-69 treated aspirations (dTT 1X at 37\u00b0C for 15min) were centrifuged, suspended in 200\u00b5L of water and", "latex": null, "type": "figure"}, "FIGREF2": {"text": "70submitted to extraction (whole nucleic acids extraction) using the GeneLead VIII extractor-thermocycler\u2122 71 (Precision System Science, Matsudo, Japan). P. jirovecii reverse transcriptase quantitative PCR (RTqPCR)", "latex": null, "type": "figure"}, "FIGREF3": {"text": "80 factors for severe COVID-19 presentation were included (Table1). All patients except one were intubated 81 on admission. Twenty-seven patients (93%) who developed ARDS received corticosteroids once 82 mechanically ventilated. Respiratory samples included 27 BALs (93%) and two bronchial aspiration fluids 83 (7%). In 5/29 patients (17%), P. jirovecii RTqPCR was positive. The median quantitative cycle value was 84 32.4 [28.9-36.5].", "latex": null, "type": "figure"}, "FIGREF4": {"text": "No significant differences were observed between P. jirovecii RTqPCR-positive and negative patients 86 in terms of age, risk factors for severe COVID-19 including prior steroid therapy, severity of ARDS, viral 87 load, blood lymphocyte count, time between intubation or onset of symptoms and SARS-CoV2 detection 88 and time between onset of symptoms, intubation or SARS-CoV2 detection and respiratory specimen 89 sampling. Interestingly, the proportion of macrophages in BAL fluids was significantly higher in P. jirovecii 90 RTqPCR-positive versus negative patients (P=0.003; Figure1), by contrast to the proportions of neutrophils 91 and lymphocytes.", "latex": null, "type": "figure"}, "FIGREF5": {"text": "102 contamination with amplicons responsible for false positives (3). In our experience using qPCR, around 103 15% of BAL fluids are positive in immunocompromised patients (3), supporting the proposal that the 104 prevalence we observed in the apparently non-immunocompromised COVID-19 patients is actually 105 elevated. These patients mostly exhibit marked lymphopenia and alterations in lymphocyte functions (6), 106 likely explaining the high-rate of P. jirovecii detection. Nevertheless, b-D-glucan concentrations measured 107 in the respiratory fluid specimens obtained in our five P. jirovecii RTqPCR-positive patients were lower 108 than 120pg/mL supporting limited fungal loads in the lung alveoli (7). Of note, in two out of our nine tested 109 P. jirovecii RTqPCR-negative patients, higher b-D-glucan concentrations (450 and 523pg/ml) lead to the 110 diagnosis of putative invasive aspergillosis, another fungal infection of risk in COVID-19 patients (8).", "latex": null, "type": "figure"}, "FIGREF6": {"text": "Surprisingly, the BAL macrophage proportion was particularly elevated in our P. jirovecii RTqPCR-112 positive COVID-19 patients. In immunocompromised adults with pneumocystosis, BAL macrophage 113 proportions of ~45% have been reported (9). Interestingly, in non-HIV patients, the count and proportion 114 of BAL macrophages was significantly increased in mild compared to severe pneumocystosis, i.e. 40.7% 115 versus 28.3% and 76 versus 50cells/\u00b5l, respectively (10). Taken together, these findings strengthen the 116 hypothesis that P. jirovecii presence in the deep lung may influence local immunity and enhance 117 inflammation. 118 Here, three out of five P. jirovecii RTqPCR-positive patients received co-trimoxazole as prophylactic 119 regimen, based on the treating physician's decision. Whether a positive result should be an indication to 120 consider administering co-trimoxazole, at least at prophylactic dosage in COVID-19 patients remains 121 questionable.", "latex": null, "type": "figure"}, "FIGREF7": {"text": "Distribution of the proportion of macrophages in the bronchoalveloar lavage (BAL) with positive or 136 negative Pneumocystis jirovecii reverse transcriptase quantitative PCR (PjRTqPCR) 137 138 .", "latex": null, "type": "figure"}, "TABREF0": {"text": "To the Editor:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is spreading pandemically with more than 3,500,000 diagnosed cases and 250,000 fatalities reported on May 07 th 202048(https://coronavirus.jhu.edu/map.html). Approximately 5-10% of coronavirus disease 2019 (COVID-19) patients may require intensive care unit (ICU) management including mechanical ventilation and 30% may develop secondary pneumonia without identified etiology (1). Hospital-acquired bacterial or fungal superinfections, as described in critically ill patients with Influenza virus, can be suspected (2). Since pneumocystosis is usually reported in patients with T-cell immunodepression (3), less attention has been paid to Pneumocystis jirovecii in non-immunocompromised ICU patients although it accounts for 7% of 54 the co-infections reported in those admitted with Influenza (4). Interestingly, COVID-19 patients may 55 develop acute respiratory distress syndrome (ARDS) requiring adjunctive steroids or other 56immunomodulatory therapies, a well-known susceptibility factor for developing pneumocystosis (4). Here, we investigated the prevalence of P. jirovecii acid nucleic detection in respiratory specimens sampled to identify co-infections in COVID-19 patients admitted to the ICU.", "latex": null, "type": "table"}, "TABREF1": {"text": "was performed to amplify mtSSU and mtLSU RNA and DNA of P. jirovecii using the new R-DiaPnJ kit\u2122 73 (Diagenode, Liege, Belgium). b-D-glucan was tested using the Fungitell kit\u2122 (Cape Cod Inc, Falmouth, US) as recommended by the manufacturer. Data are presented as median [range] or percentages as 75 appropriate. Comparisons were performed using Mann-Whitney or exact Fisher tests as required. P<0.05 was considered as significant. Twenty-nine successive COVID-19 patients (M/F sex ratio, 2.6; age, 60 years [33-80]) with the usual risk", "latex": null, "type": "table"}, "TABREF2": {"text": "Table 1. Characteristics of twenty-nine critically ill COVID-19 patients according to Pneumocystis 166 jirovecii detection in the respiratory samples 167", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Parameters </td><td>P. jirovecii RTqPCR-positive patients </td><td>P. jirovecii RTqPCR-negative patients </td><td>P Value </td></tr><tr><td>(n=5) </td><td>(n=24) </td><td>\u00a0</td></tr><tr><td>Age (years) </td><td>59 [41-79] </td><td>60 [33-80] </td><td>0.64 </td></tr><tr><td>Gender (M/F) </td><td>1.5 </td><td>3 </td><td>0.60 </td></tr><tr><td>Diabetes, N (%) </td><td>1 (20) </td><td>10 (42) </td><td>0.62 </td></tr><tr><td>Hypertension, N (%) </td><td>3 (60) </td><td>11 (46) </td><td>0.65 </td></tr><tr><td>Obesity, N (%) </td><td>0 </td><td>7 (29) </td><td>0.30 </td></tr><tr><td>Ischemic heart disease, N (%) </td><td>1 (20) </td><td>5 (21) </td><td>0.99 </td></tr><tr><td>Prior steroid therapy, N (%) </td><td>2 (40) </td><td>2 (8) </td><td>0.13 </td></tr><tr><td>PaO2/FiO2 (mmHg) </td><td>167 [79-290] </td><td>162.5 [42-480] </td><td>0.59 </td></tr><tr><td>Time from symptom start to SARS-CoV2 detection </td><td>7 [4-13] </td><td>7.5 [3-30] </td><td>0.92 </td></tr><tr><td>(days) Time from symptom start to tracheal intubation </td><td>8 [5-16] </td><td>8 [3-33] </td><td>0.72 </td></tr><tr><td>(days) Time from tracheal intubation to BAL (days) </td><td>1 [0-5] </td><td>3 [0-20] </td><td>0.25 </td></tr><tr><td>Lymphocyte count (G/L) </td><td>0.8 [0.3-1.5] </td><td>1.1 [0.3-2.8] </td><td>0.99 </td></tr><tr><td>BAL macrophages, N (%) </td><td>53 [49-72] </td><td>26 [4-46] </td><td>0.0003 </td></tr><tr><td>BAL neutrophils, N (%) </td><td>23.5 [10-32] </td><td>46 [3-87] </td><td>0.29 </td></tr><tr><td>BAL lymphocytes, N (%) </td><td>18 [10-39] </td><td>23 [1-74] </td><td>0.83 </td></tr><tr><td>\u2022-D-glucan (pg/mL) (N=13) </td><td>16.3 [7.0-105.0] </td><td>13.1 [7.8-523.0] </td><td>0.60 </td></tr><tr><td>Viral load, (cycle) </td><td>23 [17-32] </td><td>28 [15-37] </td><td>0.34 </td></tr><tr><td>Steroid administration in the ICU, %\u2020 </td><td>4 (80) </td><td>17 (71) </td><td>0.99 </td></tr><tr><td>1 (20) / 1 (20) / 3 (60) BAL, bronchoalveolar lavage; ICU, intensive care unit; RTqPCR, reverse transcriptase quantitative polymerase chain reaction; </td><td>Outcome (death / in ICU / discharged), N (%) </td><td>9 (38) / 3 (12) / 12 (50) </td><td>0.1 </td></tr></table></body></html>"}}, "back_matter": [{"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "161"}, {"text": "The copyright holder for this preprint this version posted May 22, 2020. ", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", "cite_spans": [], "ref_spans": [], "section": "68"}, {"text": "The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105296 doi: medRxiv preprint 10 \u2020Steroid regimen, dexamethasone intravenous dose of 20 mg once daily from day 1 to day 5, followed by 10 mg once daily 69 from day 6 to day 10.", "cite_spans": [], "ref_spans": [], "section": "(which was not certified by peer review)"}, {"text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105296 doi: medRxiv preprint", "cite_spans": [], "ref_spans": [], "section": "71"}]}